Children's hospitals in Cincinnati and Memphis, TN, have established the value of FDG-PET for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Children's hospitals in Cincinnati and Memphis, TN, have established the value of FDG-PET for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Lead author Dr. Susan E. Sharp, an assistant professor of clinical radiology at Cincinnati Children's Hospital Medical Center, and colleagues reviewed a total of 113 paired planar and SPECT Iodine-123I-metaiodobenzylguanidine (MIBG) and FDG-PET/CT scans in 60 patients with neuroblastoma. The investigators found that for stage 1 and stage 2 neuroblastoma patients, FDG-PET depicted more primary or residual neuroblastoma. However, they also found MIBG imaging may be needed to exclude higher stage disease that has spread to the bone or bone marrow (J Nucl Med 2009;50[8]:1237-1243).
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.